BLAINTRAMUSCULARSUSPENSION
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
3/8 — Basic
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
mRESVIA is a messenger RNA vaccine developed by Moderna for the prevention of Respiratory Syncytial Virus (RSV) infection, approved by the FDA on May 31, 2024. The vaccine uses mRNA technology to stimulate immune response against RSV, a common respiratory pathogen affecting infants, elderly, and immunocompromised populations. It is administered as an intramuscular suspension.
Growth
Early-stage growth phase with 153 linked job openings indicates rapid team expansion and sustained hiring momentum as Moderna scales manufacturing and commercial operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
Started Jun 2026
60 enrolled
Respiratory Syncytial Virus (RSV)
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
Started Oct 2025
25,000 enrolled
Respiratory Syncytial Virus (RSV)
A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Started Nov 2024
947 enrolled
RSV Immunisation
Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Started May 2024
2,226 enrolled
RSV Immunization
Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Started Feb 2024
6,300 enrolled
RSV Immunisation
Worked on mRESVIA at Moderna? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.